Erste Asset Management Gmb H Homology Medicines, Inc. Transaction History

Erste Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 26, 2024	SELL	$0.0 - $0.93 $0 - $502,200	-540,000 Closed	0 $0
Q3 2023 Nov 26, 2024	SELL	$0.84 - $1.43 $48,300 - $82,225	-57,500 Reduced 9.62%	540,000 $632 Million
Q3 2022 Nov 26, 2024	BUY	$1.55 - $3.01 $926,125 - $1.8 Million	597,500 New	597,500 $958 Million
Q2 2022 Nov 26, 2024	BUY	$1.39 - $3.12 $830,524 - $1.86 Million	597,500 New	597,500 $1.18 Billion
Q1 2022 Nov 22, 2024	BUY	$2.6 - $4.17 $884,000 - $1.42 Million	340,000 Added 132.04%	597,500 $1.82 Billion
Q4 2021 Nov 22, 2024	BUY	$3.64 - $7.78 $1.45 Million - $3.09 Million	397,500 New	397,500 $1.47 Billion
Q4 2020 Nov 22, 2024	BUY	$8.92 - $13.29 $686,840 - $1.02 Million	77,000 Added 42.66%	257,500 $3.01 Billion
Q3 2020 Nov 22, 2024	BUY	$9.94 - $16.59 $1.79 Million - $2.99 Million	180,500 New	180,500 $1.92 Billion
Q4 2019 Nov 22, 2024	BUY	$11.42 - $22.19 $1.58 Million - $3.06 Million	138,000 New	138,000 $2.9 Billion
Q2 2019 Nov 22, 2024	BUY	$18.35 - $30.34 $1.84 Million - $3.03 Million	100,000 Added 263.16%	138,000 $2.69 Billion
Q1 2019 Nov 22, 2024	BUY	$19.76 - $29.57 $750,880 - $1.12 Million	38,000 New	38,000 $1.06 Billion

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.